Bioorganic and Medicinal Chemistry Letters p. 1407 - 1410 (2004)
Update date:2022-08-03
Topics: Molecular docking Optimization Biological testing Chemical Synthesis Virtual Screening De Novo Design Preclinical and Clinical Trials
Tan, Christopher
Wei, Lianhu
Ottensmeyer, F. Peter
Goldfine, Ira
Maddux, Betty A.
Yip, Cecil C.
Batey, Robert A.
Kotra, Lakshmi P.
For the first time, a three-dimensional model of the insulin receptor is used in the de novo design of novel ligands that potentially mimic interactions of insulin at its receptor. Compound 4 competed with insulin as seen in autophosphorylation assays and inhibited up to 68% of IR autophosphorylation at 300 μM of 4 in 3T3IR cells induced by 1 nM insulin. This model provides a basis for the design of potent insulin receptor ligands.
View MoreNanjing lanbai chemical Co.,Ltd.
Contact:+86-25-85499326
Address:Room 908, 9F Taiyue Building,No.285 Heyan Road
website:https://www.bocsci.com/
Contact:1-631-485-4226
Address:Ramsey Road
Nantong Auxin Electronic Technology Co., LTD
Contact:86-513-88760026
Address:NO.5-1, Aoxin Road, Haian Hi-tech Development Zone, Jiangsu Province, China
Shanghai Mokai Pharmaceutical Co.,Ltd
Contact:021-60257269
Address:Rm506,No.915,Zhenbei Road,Shanghai,200333,China
Jiangsu Feymer Technology Co., Ltd.
Contact:+86-512-58110622/58110118
Address:Fenghuang Town, Zhangjiagang City, Jiangsu Province, China
Doi:10.3987/COM-03-S52
(2003)Doi:10.1002/jhet.5570410112
(2004)Doi:10.1021/jo502349a
(2014)Doi:10.1021/jm00119a025
(1988)Doi:10.1016/S0040-4039(98)01776-6
(1998)Doi:10.1016/j.bmcl.2016.05.026
(2016)